151 related articles for article (PubMed ID: 6262143)
21. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine.
Sawyer LA; McInnis J; Patel A; Horne AD; Albrecht P
Vaccine; 1994 Jul; 12(9):851-6. PubMed ID: 7526574
[TBL] [Abstract][Full Text] [Related]
22. Methods for the Quality Control of Inactivated Poliovirus Vaccines.
Wilton T
Methods Mol Biol; 2016; 1387():279-97. PubMed ID: 26983741
[TBL] [Abstract][Full Text] [Related]
23. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency.
Maas R; van Diepen M; Komen M; Oei H; Claassen I
Dev Biol (Basel); 2002; 111():313-8. PubMed ID: 12678255
[TBL] [Abstract][Full Text] [Related]
24. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
25. Regulation and standardization of IPV and IPV combination vaccines.
Baca-Estrada M; Griffiths E
Biologicals; 2006 Jun; 34(2):159-61. PubMed ID: 16682221
[TBL] [Abstract][Full Text] [Related]
26. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
27. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of poliovirus with beta-propiolactone.
Jiang SD; Pye D; Cox JC
J Biol Stand; 1986 Apr; 14(2):103-9. PubMed ID: 3020055
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
31. Measuring Poliovirus Antigenicity by Surface Plasmon Resonance. Application for Potency Indicating Assays.
Westdijk J; van der Maas L; Ten Have R; Kersten G
Methods Mol Biol; 2016; 1387():299-323. PubMed ID: 26983742
[TBL] [Abstract][Full Text] [Related]
32. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
Whelan SP; Evans D; Almond JW
Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
[No Abstract] [Full Text] [Related]
33. Formation of autoantibodies in laboratory animals after inoculation of viruses with different virulence. I. Results of studies on vaccine and wild strains of polio and measles viruses in guinea pigs.
Grachev VP; Popova VD; Vasilyeva IG; Avdeyeva LI
Acta Virol; 1973 Jul; 17(4):319-26. PubMed ID: 4148212
[No Abstract] [Full Text] [Related]
34. A note on single- and two-dose immunogenicity tests of inactive virus vaccine in chicks.
Slonim D; Drevo M
J Hyg Epidemiol Microbiol Immunol; 1976; 21(3):368-70. PubMed ID: 1033226
[TBL] [Abstract][Full Text] [Related]
35. The monitoring of antigen levels during inactivated poliovirus vaccine production: evaluation of filtration techniques.
Moynihan M; Petersen I
Dev Biol Stand; 1981; 50():243-8. PubMed ID: 6804290
[TBL] [Abstract][Full Text] [Related]
36. Use of ELISA for in vitro potency test of rabies vaccines for animal use.
Gamoh K; Senda M; Itoh O; Muramatsu M; Hirayama N; Koike R; Endoh YS; Minamoto N
Biologicals; 1996 Jun; 24(2):95-101. PubMed ID: 8889055
[TBL] [Abstract][Full Text] [Related]
37. A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines.
Wood DJ; Heath AB; Sawyer LA
Biologicals; 1995 Mar; 23(1):83-94. PubMed ID: 7619442
[TBL] [Abstract][Full Text] [Related]
38. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
39. [Antigenicity of 4 antiviral vaccines].
Ruiz-Gómez J
Gac Med Mex; 1973 Jun; 105(6):599-608. PubMed ID: 4731998
[No Abstract] [Full Text] [Related]
40. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
